January 06, 2010
Galvus® (vildagliptin) is a drug in a new class of oral diabetes medications, called DPP-4 inhibitors. It is available in Europe, but not in the
United States.
vildagliptin
- Brand name in US: Galvus®
- Class: DPP-4 inhibitor
- For: Type 2 diabetes
- Route of Administration: oral
- Action: inhibits DPP-4 (dipeptidyl peptidase-4), allowing potentiation of the secretion of insulin by beta cells.
- Manufacturer: Novartis
- Status: Approved in Europe February 2008. FDA asked for additional safety data, November 2006
- Source: Press release from manufacturer, Novartis: Galvus®, a new treatment for patients with type 2 diabetes, receives European approval for label update paving the way for EU launches
- Other drugs in the same class: Januvia (sitagliptin) (approved in US and Europe); Onglyza® (saxagliptin) (approved in US; undergoing EU review as of summer 2009).
